From April 2026, the Capacity and Access Improvement Payments (CAIP) have been replaced by a new national GP Reimbursement Scheme. This change moves funding control from PCNs back to individual practices, allowing contractors to claim directly for salaried GP costs under clear eligibility and additionality rules. Practices can continue CAIP‑funded posts by claiming reimbursement through the new Section 14A provisions, ensuring local flexibility while maintaining accountability for patient access and workforce expansion.
Mounjaro (tirzepatide) is now approved by NICE for obesity, but it is not yet commissioned as a LES in Doncaster. This means GPs currently cannot prescribe it for weight management, even though the new QOF obesity indicators require shared decision‑making about available treatments. Practices should continue to meet QOF requirements through accurate BMI coding, timely referrals to local weight‑management services, and documented discussions that note tirzepatide exists nationally but is not accessible locally. The LMC will update practices as soon as commissioning changes.